In­di­v­ior gets a speedy re­view for opi­oid ad­dic­tion drug as FDA vows to fight a cri­sis

With the FDA vow­ing to do every­thing in its pow­er to help fight the coun­try’s opi­oid ad­dic­tion cri­sis, reg­u­la­tors have hand­ed In­di­v­ior a pass on­to the in­side track at the agency, promis­ing a speedy re­view of its opi­oid ad­dic­tion ther­a­py.

The FDA’s pri­or­i­ty re­view process slash­es 4 months off the stan­dard 10-month ap­proach. That means In­di­v­ior {LON: IN­DV} will be up for a de­ci­sion by the end of No­vem­ber for RBP-6000, a once-month­ly slow-re­lease ver­sion of the opi­oid de­pen­dence drug buprenor­phine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.